GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on developing vaccines and immunotherapies for high-consequence infectious diseases and solid tumor cancers. The company is notable for its expedited regulatory pathway for its GEO-MVA vaccine targeting mpox and smallpox, with plans for a pivotal Phase 3 clinical trial in 2026.

Total raised
$3M
tracked to date
Latest round
Private Placement
May 18, 2026

Is this your company?

Claim this profile to get matched with investors who fund Health startups in United States.

Claim this profile →

🏆 Featured in Datapile’s Q2 2026 USA Funding Report

Read the Q2 2026 USA report →
Add this badge to your site
<a href="https://datapile.co/reports/q2-2026-usa-startup-funding" target="_blank" rel="noopener" style="display:inline-flex;align-items:center;gap:8px;padding:9px 16px;border-radius:9999px;background:#0B1224;color:#ffffff;font:600 13px/1.2 -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Arial,sans-serif;text-decoration:none;border:1px solid #7C5CFF"><span style="display:inline-block;width:11px;height:11px;border-radius:3px;background:#7C5CFF"></span>Featured in Datapile&rsquo;s Q2 2026 USA Funding Report</a>

Funding history

  1. 1
    $3MPrivate PlacementMay 18, 2026
    Announcement ↗

GeoVax Labs, Inc. in the news

Coverage of this company's funding, tracked by Datapile.

More Health companies

Recently funded startups in the same category.

Related on Datapile